BACKGROUND: High plasma concentrations of factor VIII (FVIII) and von Willebrand factor (VWF) have been recently associated with a moderately increased risk of venous thrombosis, but their roles in cerebral sinus and venous thrombosis (CSVT) have not been addressed. To determine whether elevation of FVIII and VWF is more frequent in CSVT, we analysed plasma levels of FVIII and VWF in a case control study. METHODS: The study population consisted of 25 consecutive patients (of whom nine were excluded) admitted for CSVT to the Department of Neurology, Amiens University Hospital, France, from January 1997 to December 2002, for a general screening for thrombophilia. Sixty-four healthy subjects matched for age and sex formed the group control. RESULTS: Mean FVIII (CSVT: 167.3 (SD 48.8) IU/dl; control group: 117.9 (39.8) IU/dl; p = 0.001) and VWF levels (CSVT: 165.4 (76.5)%; control group: 108.5 (27.8)%; p = 0.01) were significantly higher in the CSVT group. Using the 95th percentile of the control group as the cut off value, elevated FVIII (>190 IU/dl) occurred in 25% (4/16) (p = 0.005) and elevated VWF (>168%) in 37.5% (6/16) of patients with CSVT (p<0.001). Using previously reported cut off values (>150 IU/dl or >150%) showed the same results (FVIII: p = 0.005; VWF: p = 0.009). CONCLUSION: Our study suggests that elevation of plasma factor VIII levels is the most common prothrombotic risk factor for CSVT. Elevation of VWF is also associated with an increased risk of CSVT but its effect seems to be partly mediated through FVIII.
BACKGROUND: High plasma concentrations of factor VIII (FVIII) and von Willebrand factor (VWF) have been recently associated with a moderately increased risk of venous thrombosis, but their roles in cerebral sinus and venous thrombosis (CSVT) have not been addressed. To determine whether elevation of FVIII and VWF is more frequent in CSVT, we analysed plasma levels of FVIII and VWF in a case control study. METHODS: The study population consisted of 25 consecutive patients (of whom nine were excluded) admitted for CSVT to the Department of Neurology, Amiens University Hospital, France, from January 1997 to December 2002, for a general screening for thrombophilia. Sixty-four healthy subjects matched for age and sex formed the group control. RESULTS: Mean FVIII (CSVT: 167.3 (SD 48.8) IU/dl; control group: 117.9 (39.8) IU/dl; p = 0.001) and VWF levels (CSVT: 165.4 (76.5)%; control group: 108.5 (27.8)%; p = 0.01) were significantly higher in the CSVT group. Using the 95th percentile of the control group as the cut off value, elevated FVIII (>190 IU/dl) occurred in 25% (4/16) (p = 0.005) and elevated VWF (>168%) in 37.5% (6/16) of patients with CSVT (p<0.001). Using previously reported cut off values (>150 IU/dl or >150%) showed the same results (FVIII: p = 0.005; VWF: p = 0.009). CONCLUSION: Our study suggests that elevation of plasma factor VIII levels is the most common prothrombotic risk factor for CSVT. Elevation of VWF is also associated with an increased risk of CSVT but its effect seems to be partly mediated through FVIII.
Authors: A Jager; V W van Hinsbergh; P J Kostense; J J Emeis; J S Yudkin; G Nijpels; J M Dekker; R J Heine; L M Bouter; C D Stehouwer Journal: Arterioscler Thromb Vasc Biol Date: 1999-12 Impact factor: 8.311
Authors: C M Schambeck; K Hinney; I Haubitz; B Mansouri Taleghani; D Wahler; F Keller Journal: Arterioscler Thromb Vasc Biol Date: 2001-02 Impact factor: 8.311
Authors: S Cakmak; L Derex; M Berruyer; N Nighoghossian; F Philippeau; P Adeleine; M Hermier; J C Froment; P Trouillas Journal: Neurology Date: 2003-04-08 Impact factor: 9.910
Authors: Philip S Wells; Nicole J Langlois; Marc A Webster; James Jaffey; Josdalyne A Anderson Journal: Thromb Haemost Date: 2005-05 Impact factor: 5.249
Authors: P A Kyrle; E Minar; M Hirschl; C Bialonczyk; M Stain; B Schneider; A Weltermann; W Speiser; K Lechner; S Eichinger Journal: N Engl J Med Date: 2000-08-17 Impact factor: 91.245
Authors: P E Morange; C Simon; M C Alessi; G Luc; D Arveiler; J Ferrieres; P Amouyel; A Evans; P Ducimetiere; I Juhan-Vague Journal: Circulation Date: 2004-03-15 Impact factor: 29.690
Authors: Albert W Tsai; Mary Cushman; Wayne D Rosamond; Susan R Heckbert; Russell P Tracy; Nena Aleksic; Aaron R Folsom Journal: Am J Med Date: 2002-12-01 Impact factor: 4.965